Work

3. SMART Medical Review: CA 19-9 and pancreatic ductal adenocarcinoma (PDAC).

Year: 2024

Type: article

Abstract: Carbohydrate antigen 19-9 (CA 19-9) is the sole FDA-approved serum biomarker for early detection, progression, and treatment response of pancreatic ductal adenocarcinoma (PDAC, pancreatic cancer). It is more specific than other serum biomarkers for PDAC. Understanding the clinical relevance of genetic variants and other conditions on CA 19-9 expression is thus critical for proper interpretation. This review covers PDAC risk assessment, screening, early diagnosis and treatment monitoring with a focus on CA 19-9 and genetic factors that influence serum levels with or without PDAC.

Source: SMART-MD journal of precision medicine.

DOI: 10.69734/psc3br75

Authors: David Whitcomb, Talia DeFrancesco Oranburg, Rhea Vallente, Randall E Brand

Institutions: University of Pittsburgh, University of Pittsburgh Medical Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W4399468102

FWCI: 0.687

Cites:

Cited by: 4

Related to: 10